文献速递临床试验与 GCP流行病学与生物统计

在魁北克既往一次剖宫产妇女中降低主要围产期发病率的整群随机试验(PRISMA试验):随机对照试验研究方案

A cluster-randomized trial to reduce major perinatal morbidity among women with one prior cesarean delivery in Québec (PRISMA trial): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2017-09-20

该研究为在魁北克开展的整群随机平行组试验,以医院为随机单位、妇女为分析单位,评估多层面干预能否降低既往一次剖宫产妇女的主要围产期发病率。研究包括1年基线期、5个月实施期和2年干预期,20家医院分配至干预组、20家至对照组,主要结局为干预期主要围产期发病率复合指标。

要点

  • 多层面干预包括决策分析工具、超声评估子宫下段厚度、剖宫产后阴道分娩成功预测工具及产时最佳实践。
  • 主要结局为干预期主要围产期发病率复合指标,次要结局包括孕产妇发病、试产率和剖宫产后阴道分娩率。
  • 采用多变量广义估计方程扩展的logistic回归评估干预效果,并开展早产与足月亚组分析及成本效果分析。

核心结论

  • 该试验旨在评估多层面干预是否降低既往一次剖宫产妇女的主要围产期发病率。

研究设计与样本

  • 研究为分层、非盲法、整群随机、平行组试验,以魁北克医院为随机单位、妇女为分析单位。
  • 研究包括1年干预前基线期、5个月实施期和2年干预期,基线期末将20家医院分配至干预组、20家至对照组,随机化按医疗级别分层。
  • 数据通过病历在干预前和干预期收集,采用多变量广义估计方程扩展的logistic回归评估干预效果。

主要发现

  • 原文为研究方案,未报告试验结果。

关键数值与推荐

  • 主要结局为干预期测量的主要围产期发病率复合指标的发生率。
  • 次要结局包括主要和次要孕产妇发病率、次要围产期发病率以及试产率和剖宫产后阴道分娩率。
  • 评估包括早产和足月分娩的亚组分析及成本效果分析。

临床怎么用

  • 干预设计旨在促进:使用决策分析工具辅助妇女决策;通过超声评估子宫下段厚度估计试产期间子宫破裂风险;使用经过验证的预测工具估计试产成功机会;实施产时管理最佳实践。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rates of cesarean delivery are continuously increasing in industrialized countries, with repeated cesarean accounting for about a third of all cesareans. Women who have undergone a first cesarean are facing a difficult choice for their next pregnancy, i.e.: (1) to plan for a second cesarean delivery, associated with higher risk of maternal complications than vaginal delivery; or (b) to have a trial of labor (TOL) with the aim to achieve a vaginal birth after cesarean (VBAC) and to accept a significant, but rare, risk of uterine rupture and its related maternal and neonatal complications. The objective of this trial is to assess whether a multifaceted intervention would reduce the rate of major perinatal morbidity among women with one prior cesarean. METHODS/DESIGN: The study is a stratified, non-blinded, cluster-randomized, parallel-group trial of a multifaceted intervention. Hospitals in Quebec are the units of randomization and women are the units of analysis. As depicted in Figure 1, the study includes a 1-year pre-intervention period (baseline), a 5-month implementation period, and a 2-year intervention period. At the end of the baseline period, 20 hospitals will be allocated to the intervention group and 20 to the control group, using a randomization stratified by level of care. Medical records will be used to collect data before and during the intervention period. Primary outcome is the rate of a composite of major perinatal morbidities measured during the intervention period. Secondary outcomes include major and minor maternal morbidity; minor perinatal morbidity; and TOL and VBAC rate. The effect of the intervention will be assessed using the multivariable generalized-estimating-equations extension of logistic regression. The evaluation will include subgroup analyses for preterm and term birth, and a cost-effectiveness analysis. DISCUSSION: The intervention is designed to facilitate: (1) women's decision-making process, using a decision analysis tool (DAT), (2) an estimate of uterine rupture risk during TOL using ultrasound evaluation of low-uterine segment thickness, (3) an estimate of chance of TOL success, using a validated prediction tool, and (4) the implementation of best practices for intrapartum management. TRIAL REGISTRATION: Current Controlled Trials, ID: ISRCTN15346559 . Registered on 20 August 2015.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Chaillet N, Bujold E, Masse B, et al. A cluster-randomized trial to reduce major perinatal morbidity among women with one prior cesarean delivery in Québec (PRISMA trial): study protocol for a randomized controlled trial. Trials. 2017. PMID: 28931404. doi:10.1186/s13063-017-2150-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。